CONIVAPTAN HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C32H26N4O2.ClH
Molecular Weight	535.035
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC1=NC2=C(N1)C3=CC=CC=C3N(CC2)C(=O)C4=CC=C(NC(=O)C5=CC=CC=C5C6=CC=CC=C6)C=C4

InChI

InChIKey=BTYHAFSDANBVMJ-UHFFFAOYSA-N

InChI=1S/C32H26N4O2.ClH/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22;/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37);1H

HIDE SMILES / InChI

Molecular Formula	C32H26N4O2
Molecular Weight	498.5744
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/ppa/conivaptan.html
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21409494 | https://www.ncbi.nlm.nih.gov/pubmed/18926434

Conivaptan is an arginine vasopressin (AVP) receptor antagonist with affinity for AVP receptor subtypes V1A and V2. The antidiuretic action of AVP is mediated through activation of the V2 receptor, which functions to regulate water and electrolyte balance at the level of the collecting ducts in the kidney. Conivaptan was approved in 2004 for hyponatremia caused by syndrome of inappropriate antidiuretic hormone. Conicaptan is being evaluated for reduce intracranial pressure in patients with traumatic brain injury, and as a treatment for heart failure.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vasopressin V1a receptor 18 Target ID: CHEMBL1889 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	Antagonist 2849		0.43 nM [Ki]
Vasopressin V2 receptor 16 Target ID: CHEMBL1790 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	Antagonist 2849		0.36 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Hyponatremia 4 Sources: https://www.drugs.com/ppa/conivaptan.html	Primary	Approved 8583	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER Approved Use VAPRISOL is a vasopressin receptor antagonist indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia. Launch Date 2005
Traumatic brain injury 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21409494	Palliative	Phase I 438	Unknown Approved Use Unknown
Liver cirrhosis 15 Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	Palliative	Phase II 1147	Unknown Approved Use Unknown
Heart failure 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18926434	Palliative	Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
619 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	40 mg/kg single, intravenous dose: 40 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2681 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10638391	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4813 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10638391	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	40 mg/kg single, intravenous dose: 40 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.1 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10638391	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021697s003lbl.pdf	40 mg/kg single, intravenous dose: 40 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CONIVAPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16522696	unhealthy, 68.7 years (range: 35–90 years) Health Status: unhealthy Age Group: 68.7 years (range: 35–90 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16522696	Sources: https://pubmed.ncbi.nlm.nih.gov/16522696
120 mg 1 times / day multiple, intravenous Highest studied dose Dose: 120 mg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf	Other AEs: Hypotension, Thirst... Other AEs: Hypotension Thirst Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf
40 mg 1 times / day multiple, intravenous Recommended Dose: 40 mg, 1 times / day Route: intravenous Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf	Disc. AE: Hypopituitarism, Infusion site reaction... AEs leading to discontinuation/dose reduction: Hypopituitarism (0.2%) Infusion site reaction (0.2%) Infusion site phlebitis (1.6%) Infusion related reaction (0.2%) Sepsis NOS (0.2%) Pneumonia NOS (0.2%) Blood creatinine increased (0.2%) Blood sodium increased (0.2%) Blood urea increased (0.2%) Heart rate increased (0.2%) Hypernatremia (0.8%) Epilepsy NOS (0.2%) Agitation (0.2%) Renal failure acute (0.2%) Respiratory arrest (0.2%) Respiratory failure (0.2%) Cyanosis peripheral (0.2%) Phlebitis NOS (0.2%) Phlebitis superficial (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf
12.5 mg single, intravenous Dose: 12.5 mg Route: intravenous Route: single Dose: 12.5 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	Other AEs: Dizziness... Other AEs: Dizziness (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00592475
20 mg 1 times / day multiple, intravenous Dose: 20 mg, 1 times / day Route: intravenous Route: multiple Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	Other AEs: Coagulopathy, Cardiac failure congestive... Other AEs: Coagulopathy (serious, 1 patient) Cardiac failure congestive (serious, 2 patients) Multi-organ failure (serious, 1 patient) Hyponatraemia (serious, 1 patient) Transient ischaemic attack (serious, 1 patient) Renal failure (serious, 1 patient) Respiratory distress (serious, 1 patient) Hypocoagulable state (below serious, 1 patient) Leukocytosis (below serious, 1 patient) Arrhythmia ventricular (below serious, 1 patient) Abdominal discomfort (below serious, 1 patient) Abdominal distension (below serious, 2 patients) Abnormal bowel sounds (below serious, 1 patient) Constipation (below serious, 2 patients) Nausea (below serious, 2 patients) Fatigue (below serious, 1 patient) Hypothermia (below serious, 1 patient) Pain (below serious, 2 patients) Procedural pain (below serious, 1 patient) Breath sounds abnormal (below serious, 1 patient) Chest X-ray abnormal (below serious, 1 patient) Hypoalbuminaemia (below serious, 1 patient) Hypomagnesaemia (below serious, 2 patients) Hypophosphataemia (below serious, 1 patient) Hypovolaemia (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Headache (below serious, 1 patient) Lethargy (below serious, 1 patient) Anxiety (below serious, 1 patient) Dysuria (below serious, 1 patient) Cough (below serious, 1 patient) Postnasal drip (below serious, 1 patient) Rales (below serious, 1 patient) Pruritus (below serious, 1 patient) Hypotension (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00478192
20 mg 2 times / day multiple, intravenous Dose: 20 mg, 2 times / day Route: intravenous Route: multiple Dose: 20 mg, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00478192	Other AEs: Cardiac failure congestive, Pneumonia... Other AEs: Cardiac failure congestive (serious, 1 patient) Pneumonia (serious, 1 patient) Respiratory acidosis (serious, 1 patient) Coronary artery bypass (serious, 1 patient) Hypotension (serious, 1 patient) Dry eye (below serious, 1 patient) Constipation (below serious, 2 patients) Nausea (below serious, 1 patient) Vomiting (below serious, 2 patients) Chest pain (below serious, 1 patient) Fatigue (below serious, 1 patient) Oedema peripheral (below serious, 1 patient) Bronchitis chronic (below serious, 1 patient) Contusion (below serious, 1 patient) Blood pressure decreased (below serious, 1 patient) Cardiac murmur (below serious, 1 patient) Carotid bruit (below serious, 1 patient) Heart sounds abnormal (below serious, 1 patient) Dehydration (below serious, 1 patient) Hypernatraemia (below serious, 1 patient) Hypokalaemia (below serious, 1 patient) Neck pain (below serious, 1 patient) Headache (below serious, 1 patient) Insomnia (below serious, 2 patients) Psychotic disorder (below serious, 1 patient) Haematuria (below serious, 1 patient) Pruritus (below serious, 1 patient) Haematoma (below serious, 1 patient) Thrombophlebitis (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00478192
22.5 mg single, intravenous Dose: 22.5 mg Route: intravenous Route: single Dose: 22.5 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00592475	Other AEs: Atrial tachycardia, Urinary tract infection... Other AEs: Atrial tachycardia (serious, 1 patient) Urinary tract infection (serious, 1 patient) Encephalopathy hepatic (serious, 1 patient) Atrial flutter (below serious, 1 patient) Nausea (below serious, 1 patient) Vomiting (below serious, 1 patient) Polydipsia (below serious, 1 patient) Back pain (below serious, 1 patient) Productive cough (below serious, 1 patient) Dry skin (below serious, 1 patient) Phlebitis (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00592475
60 mg single, intravenous Dose: 60 mg Route: intravenous Route: single Dose: 60 mg Sources: https://clinicaltrials.gov/ct2/show/NCT00843986	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00843986	Other AEs: Cardiac arrest, Atrial flutter... Other AEs: Cardiac arrest (serious, 1 patient) Atrial flutter (below serious, 1 patient) Ventricular tachycardia (below serious, 1 patient) Constipation (below serious, 1 patient) Infusion site erythema (below serious, 3 patients) Infusion site pain (below serious, 1 patient) Pyrexia (below serious, 1 patient) Heart rate increased (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Pain in extremity (below serious, 1 patient) Headache (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00843986

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 CYP1A2 2153 CYP2C19 2057	P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 20, 48	strong [IC50 0.47 uM]	yes (co-administration study) Comment: coadministration with midazolam or simvastatin significantly increased both CYP3A4 substrates Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 20, 48
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 48.0	weak [IC50 198.3 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 48.0	yes [IC50 12.6 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 48	yes [IC50 13.3 uM]	yes (co-administration study) Comment: coadministration with warfarin increased warfarin WUC by 14% amd Cmax by 17% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 48
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 48.0	yes [IC50 19.2 uM]
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 21	yes	yes (co-administration study) Comment: coadministration with digoxin resulted in increased Cmax by 79% and AUC by 43% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021697s005lbl.pdf Page: 10, 21

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 21, 48	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 38.0	yes		yes (co-administration study) Comment: ketoconazole increased conivaptan AUC 11-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_BIOPHARMR.pdf Page: 38.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_PHARMR.pdf Page: 20, 25

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:681850	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:681850
ChemicalBook	CB51011161	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51011161
MolPort	MolPort-046-703-477	https://www.molport.com/shop/molecule-link/MolPort-046-703-477
ZINC	ZINC000012503187	http://zinc15.docking.org/substances/ZINC000012503187

PubMed

Title	Date	PubMed
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.	2009-07	19542534
AVP receptor antagonists in patients with CHF.	2009-06	18766439
Pharmacology of vasopressin antagonists.	2009-06	18766438
Hyponatremia: case vignettes.	2009-05	19523576
Medial septal area vasopressin receptor subtypes in the regulation of urine and sodium excretion in rats.	2009-02	19076265
New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia.	2009-01	19151543
Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.	2009-01	19057376
Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome.	2009	19169014
Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.	2009	19123060
Conivaptan for hyponatremia in the neurocritical care unit.	2009	19003543
Vasopressin and vasopressin receptor antagonists in heart failure.	2008-12-19	19092365
Tolvaptan and its potential in the treatment of hyponatremia.	2008-12	19337422
Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?	2008-10	18926435
Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.	2008-10	18926434
Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.	2008-08	18437428
[Etiology, diagnostics and therapy of hyponatremias].	2008-07-20	18617466
Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.	2008-07	18034777
Vasopressin and vasopressin antagonists in heart failure and hyponatremia.	2008-06	18765079
Conivaptan: potential therapeutic implications in heart failure.	2008-06	18537764
Non-peptide arginine-vasopressin antagonists: the vaptans.	2008-05-10	18468546
Vasopressin-receptor antagonists in heart failure.	2008-05-01	18436727
[Pharmacology and clinical relevance of vasopressin antagonists].	2008-05	18335184
Conivaptan: a step forward in the treatment of hyponatremia?	2008-04	18728836
The management of ascites and hyponatremia in cirrhosis.	2008-02	18293276
Intravenous conivaptan.	2008	18828645
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.	2008	18655903
Mechanisms, risks, and new treatment options for hyponatremia.	2008	18434717
Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.	2008	18363040
Hyponatremia in psychiatric patients: update on evaluation and management.	2008	18306096
Diagnosis and management of hyponatremia in cancer patients.	2007-12	17701059
Current issues for nurse practitioners: Hyponatremia.	2007-11	17970857
Hyponatremia and vasopressin antagonism in congestive heart failure.	2007-11	17847041
Water in health and disease: new aspects of disturbances in water metabolism.	2007-10	17954951
Gateways to clinical trials.	2007-09	17982511
[Vasopressin antagonists in treatment of hyponatremia].	2007-08	18018383
Hyponatremia: clinical diagnosis and management.	2007-08	17679119
Conivaptan: new treatment for hyponatremia.	2007-07-01	17592003
Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers.	2007-06-15	17565921
[Recent progress in vasopressin research on cardiovascular diseases].	2007-06	17657988
Clinical practice. The syndrome of inappropriate antidiuresis.	2007-05-17	17507705
Hyponatremia: current treatment strategies and the role of vasopressin antagonists.	2007-05	17405824
New agents for managing hyponatremia in hospitalized patients.	2007-02-01	17244874
Recognition and treatment of hyponatremia in acutely ill hospitalized patients.	2007-02	17472815
Management of hyponatremia and clinical use of vasopressin antagonists.	2007-02	17301588
New drugs 07, part I.	2007-02	17273084
Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].	2007	17919259
Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.	2007	17664863
Therapeutic potential of vasopressin receptor antagonists.	2007	17428103
Cerebral correlates of hyponatremia.	2007	17356196
Vasopressin receptor antagonists in heart failure.	2006-06	18232127

Patents

Sample Use Guides

In Vivo Use Guide

IV: 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2 to 4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium not rising sufficiently; total duration of therapy not to exceed 4 days. Note: If patient requires 40 mg/24 hours, may administer two consecutive 20 mg/100 mL premixed solutions over 24 hours (ie, 20 mg over 12 hours followed by 20 mg over 12 hours).

Route of Administration: Intravenous

In Vitro Use Guide

Binding of conivaptan with recombinant human vasopressin V1a and V2 receptors was studied using [3H]-Arg-vasopressin as a radioligand. Conivaptan binds to V1a with Ki of 0.43 and to V2 receptor with Ki of 0.36 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:08:32 GMT 2025` Edited by `admin` on `Mon Mar 31 18:08:32 GMT 2025`
Record UNII	75L57R6X36
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CONIVAPTAN HCL

Preferred Name

English

CONIVAPTAN HYDROCHLORIDE

Official Name

English

CONIVAPTAN HCL [VANDF]

Common Name

English

Conivaptan Hydrochloride [WHO-DD]

Common Name

English

YM-087

Code

English

CONIVAPTAN HYDROCHLORIDE [JAN]

Common Name

English

CONIVAPTAN HYDROCHLORIDE [MI]

Common Name

English

CI-1025

Code

English

YM087

Code

English

CONIVAPTAN HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

CONIVAPTAN HYDROCHLORIDE [USAN]

Common Name

English

(1,1'-BIPHENYL)-2-CARBOXAMIDE, N-(4-((4,5-DIHYDRO-2-METHYLIMIDAZO(4,5-D)(1)BENZAZEPIN-6(1H)-YL)CARBONYL)PHENYL)-, MONOHYDROCHLORIDE

Common Name

English

VAPRISOL

Brand Name

English

CONIVAPTAN HYDROCHLORIDE [MART.]

Common Name

English

4''-((4,5-DIHYDRO-2-METHYLIMIDAZO(4,5-D)(1)BENZAZEPIN-6(1H)-YL)CARBONYL)-2-BIPHENYLCARBOXANILIDE MONOHYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2180